Fenofibrate improves age-related endothelial dysfunction in rat resistance arteries

Atherosclerosis

Volumn 193, Issue 1, 2007, Pages 112-120

  Alvarez de Sotomayor, Maria ^a   Mingorance, Carmen ^a   Andriantsitohaina, Ramaroson ^b  

^a UNIVERSITY OF SEVILLE   (Spain)

^b Universite d'Angers   (France)

Author keywords

Ageing; Cyclo oxygenase; Endothelial dysfunction; Fenofibrate; Mesenteric arteries; Superoxide dismutase

Indexed keywords

15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; 6 OXOPROSTAGLANDIN F1 ALPHA; COPPER ZINC SUPEROXIDE DISMUTASE; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; ENDOTHELIAL NITRIC OXIDE SYNTHASE; FENOFIBRATE; MANGANESE SUPEROXIDE DISMUTASE; NITRIC OXIDE SYNTHASE; THROMBOXANE B2;

AGING; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERY RESISTANCE; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; ENDOTHELIAL DYSFUNCTION; MALE; MESENTERIC ARTERY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; VASOCONSTRICTION; VASODILATATION;

AGING; ANIMALS; ANTILIPEMIC AGENTS; BLOOD GLUCOSE; CHOLESTEROL; ENDOTHELIUM, VASCULAR; MALE; MESENTERIC ARTERIES; NITRIC OXIDE; NITRIC OXIDE DONORS; PROCETOFEN; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; RATS; RATS, WISTAR; REACTIVE OXYGEN SPECIES; TRIGLYCERIDES; VASCULAR RESISTANCE; VASODILATION;

EID: 34248662090     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2006.08.041     Document Type: Article

References (34)

1. Taddei S., Galetta F., Virdis A., et al. Physical activity prevents age-related impairment in nitric oxide availability in elderly athletes. Circulation 101 (2000) 2896-2901
2. Matz R.L., Alvarez de Sotomayor M., Schott C., Stoclet J.C., and Andriantsitohaina R. Vascular bed heterogeneity in age-related endothelial dysfunction with respect to NO and eicosanoids. Br J Pharmacol 131 (2000) 303-311
3. Matz R.L., and Andriantsitohaina R. Age-related endothelial dysfunction: potential implications for pharmacotherapy. Drugs Aging 20 (2003) 527-550
4. Kersten S., Desvergne B., and Wahli W. Roles of PPARs in health and disease. Nature 405 (2000) 421-424
5. Delerive P., De Bosscher K., Besnerd S., et al. Peroxisome proliferator-activated receptor α negatively regulates the vascular inflammation gene response by negative cross-talk with transcription factors NF-κB and AP-1. J Biol Chem 274 (1999) 32048-32054
6. Staels B., Koenig W., Habib A., et al. Activation of human aortic smooth-muscle cells is inhibited by PPARα but not PPARγ activators. Nature 393 (1998) 790-793
7. Tabernero A., Schoonjans K., Jessel L., et al. Activation of the peroxisome proliferator-activated receptor α protects against myocardial ischaemic injury and improves endothelial vasodilatation. BMC Pharmacol 2 (2002) 10
8. Playford D.A., Watts G.F., Best J.D., and Burke V. Effect of fenofibrate on brachial artery flow-mediated dilatation in type 2 diabetes mellitus. Am J Cardiol 90 (2002) 1254-1257
9. Capell W.H., DeSouza C.A., Poirier P., et al. Short-term triglyceride lowering with fenofibrate improves vasodilator function in subjects with hypertriglyceridemia. Arterioscler Thromb Vasc Biol 23 (2003) 307-313
10. Keech A., Simes R.J., Barter P., et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 366 (2005) 1849-1861
11. Staels B., Peinado-Onsurbe J., and Auwerx J. Down-regulation of hepatic lipase gene expression and activity by fenofibrate. Biochim Biophys Acta 1123 (1992) 227-230
12. Staels B., van Tol A., Skretting G., and Auwerx J. Lecithin:cholesterol acyltransferase gene expression is regulated in a tissue-selective manner by fibrates. J Lipid Res 33 (1992) 727-735
13. Montanaro M.A., Bernasconi A.M., Gonzalez M.S., Rimoldi O.J., and Brenner R.R. Effects of fenofibrate and insulin on the biosynthesis of unsaturated fatty acids in streptozotocin diabetic rats. Prostaglandins Leukot Essent Fatty Acids 73 (2005) 369-378
14. Naderali E.K., Fatani S., and Williams G. Fenofibrate lowers adiposity and corrects metabolic abnormalities, but only partially restores endothelial function in dietary obese rats. Atherosclerosis 177 (2004) 307-312
15. Miki Y. A homogeneous assay for the selective measurement of LDL-cholesterol in serum. Enzymatic selective protection method. Clin Lab 45 (1999) 398-401
16. Pradelles P., Grasi J., and Maclouf J. Enzyme inmunoassays of eicosanoids using acetylcholine esterase as label: an alternative to radioinmunoassay. Anal Chem 57 (1985) 1170-1173
17. Ceda G.P., DalĺAglio E., Magnacavallo A., et al. The insulin-like growth factor axis and plasma lipoprotein levels in the elderly. J Clin Endocrinol Metab 83 (1998) 499-502
18. Van Liew J.B., Davis P.J., Davis F.B., et al. Effects of aging, diet, and sex on plasma glucose, fructosamine, and lipid concentration in barried Fisher 344 rats. J Gerontol 48 (1993) B184-B190
19. Mulas M.F., Demuro G., and Mulas C. Dietary restriction counteracts age-related changes in cholesterol metabolism in the rat. Mech Ageing Dev 126 (2005) 648-654
20. Brown K.A., Chu Y., Lund D.D., Heistad D.D., and Faraci F.M. Gene transfer of extracellular superoxide dismutase protects against vascular dysfunction with aging. Am J Physiol Heart Circ Physiol 290 (2006) H2600-H2605
21. Guerre-Millo M., Gervois P., Raspe E., et al. Peroxisome proliferator-activated receptor alpha activators improve insulin sensitivity and reduce adiposity. J Biol Chem 275 (2000) 16638-16642
22. Erol A. PPARα activators may be good candidates as antiaging agents. Med Hypotheses 65 (2005) 35-38
23. Ye P., Wang Z.J., Zhang X.J., and Zhao Y.L. Age-related decrease in expression of peroxisome proliferator-activated receptor alpha and its effects on development of dyslipemia. Chin Med J 118 (2005) 1093-1098
24. Sanguino E., Roglans N., Alegret M., et al. Atorvastatin reverses age-related reduction in rat hepatic PPARalpha and HNF-4. Br J Pharmacol 145 (2005) 853-861
25. Sung B., Park S., Yu B.P., and Chung H.Y. Modulation of PPAR in aging, inflammation, and calorie restriction. J Gerontol A Biol Sci Med Sci 59 (2004) 997-1006
26. Iemitsu M., Miyauchi T., Maeda S., et al. Aging-induced decrease in the PPAR-alpha level in hearts is improved by exercise training. Am J Physiol Heart Circ Physiol 283 (2002) H1750-H1760
27. Buchan K.W., and Hassall D.G. PPAR agonists as direct modulators of the vessel wall in cardiovascular disease. Med Res Rev 20 (2000) 350-366
28. Goya K., Sumitani S., Xu X., et al. Peroxisome proliferator-activated receptor α agonists increase nitric oxide synthase expression in vascular endothelial cells. Arterioscler Thromb Vasc Biol 24 (2004) 658-663
29. Hu Z.Z., Kerb R., Shi X.Y., Wei-Lavery T., and Hoffman B.B. Angiotensin II increases expression of cyclooxygenase-2: implications for the function of vascular smooth muscle cells. J Pharmacol Exp Ther 303 (2002) 563-573
30. Poynters M.E., and Daynes R.A. Peroxisome proliferator-activated receptor α activation modulates cellular redox status, represses nuclear factor-κB signaling, and reduces inflammatory cytokine production in aging. J Biol Chem 273 (1998) 32833-32841
31. Csiszar A., Ungvari Z., Edwards J.G., et al. Aging-induced phenotypic changes and oxidative stress impair coronary arteriolar function. Circ Res 90 (2002) 1159-1166
32. Oury T.D., Day B.J., and Crapo J.D. Extracellular superoxide dismutase in vessels and airways of humans and baboons. Free Radic Biol Med 20 (1996) 957-965
33. Adachi T., Wang J., and Wang X.L. Age-related change of plasma extracellular-superoxide dismutase. Clin Chim Acta 290 (2000) 169-178
34. Nozik-Grayck E., Suliman H.B., and Piantadosi C.A. Extracellular superoxide dismutase. Int J Biochem Cell Biol 37 (2005) 2466-2471